Jenburkt Pharmaceuticals Ltd approves Q2 and H1 FY27 unaudited results, reporting Q2 revenue of ₹48.32 crore and net profit of ₹10.21 crore.
- Q2 revenue rose 36.1% sequentially and 6.1% year on year; net profit increased 73.5% sequentially and 0.5% year on year.
- Derived operating margin was approximately 25.3%.
- No exceptional items were reported in Q2 or H1; the auditor’s limited review conclusion was unmodified.